These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12086883)

  • 1. Functional genomics and the breast cancer problem.
    Ince TA; Weinberg RA
    Cancer Cell; 2002 Feb; 1(1):15-7. PubMed ID: 12086883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers.
    Bell R; Barraclough R; Vasieva O
    Curr Mol Med; 2017; 17(3):200-210. PubMed ID: 28782484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
    Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
    Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.
    O'Connell P; Fischbach K; Hilsenbeck S; Mohsin SK; Fuqua SA; Clark GM; Osborne CK; Allred DC
    J Natl Cancer Inst; 1999 Aug; 91(16):1391-7. PubMed ID: 10451444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
    Canevari RA; Marchi FA; Domingues MA; de Andrade VP; Caldeira JR; Verjovski-Almeida S; Rogatto SR; Reis EM
    Tumour Biol; 2016 Oct; 37(10):13855-13870. PubMed ID: 27485113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic signatures of breast cancer metastasis.
    Urquidi V; Goodison S
    Cytogenet Genome Res; 2007; 118(2-4):116-29. PubMed ID: 18000362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer?
    Dirix L; Van Dam P; Vermeulen P
    Curr Opin Oncol; 2005 Nov; 17(6):551-8. PubMed ID: 16224232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systems biology and genomics of breast cancer.
    Perou CM; Børresen-Dale AL
    Cold Spring Harb Perspect Biol; 2011 Feb; 3(2):. PubMed ID: 21047916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-Roads to Drug Resistance and Metastasis in Breast Cancer: miRNAs Regulatory Function and Biomarker Capability.
    Naser Al Deen N; Nassar F; Nasr R; Talhouk R
    Adv Exp Med Biol; 2019; 1152():335-364. PubMed ID: 31456193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of genetic alterations in brain metastases of sporadic breast carcinomas is associated with reduced survival after metastasis.
    Hampl M; Hampl JA; Schwarz P; Frank S; Hahn M; Schackert G; Saeger HD; Schackert HK
    Invasion Metastasis; 1998-1999; 18(2):81-95. PubMed ID: 10364688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genomic ruler to assess oncogenic transition between breast tumor and stroma.
    Dhage S; Ernlund A; Ruggles K; Axelrod D; Berman R; Roses D; Schneider RJ
    PLoS One; 2018; 13(10):e0205602. PubMed ID: 30325954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signaling pathways in breast cancer metastasis - novel insights from functional genomics.
    Blanco MA; Kang Y
    Breast Cancer Res; 2011 Mar; 13(2):206. PubMed ID: 21457525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
    Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
    Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Integrative Approach for Identifying Network Biomarkers of Breast Cancer Subtypes Using Genomic, Interactomic, and Transcriptomic Data.
    Firoozbakht F; Rezaeian I; D'agnillo M; Porter L; Rueda L; Ngom A
    J Comput Biol; 2017 Aug; 24(8):756-766. PubMed ID: 28650678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers for the identification of late breast cancer recurrence.
    Sestak I; Cuzick J
    Breast Cancer Res; 2015 Jan; 17(1):10. PubMed ID: 25848913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.
    Yates LR; Desmedt C
    Clin Cancer Res; 2017 Jun; 23(11):2630-2639. PubMed ID: 28572257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
    BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-Expression-Based Predictors for Breast Cancer.
    Gupta A; Mutebi M; Bardia A
    Ann Surg Oncol; 2015 Oct; 22(11):3418-32. PubMed ID: 26215189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.